Lung Cancer, Non-small Cell Lung Cancer
Conditions
Keywords
NSCLC, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Thoracic Neoplasms
Brief summary
The Moffitt Cancer Center and PatientsLikeMe.com (PLM), an online patient community, are working together to better understand the patient's entire lung cancer experience, both inside and outside the doctor's office. By combining the data that is captured by their care team in the clinic with the data participants enter at their home on PatientsLikeMe.com, the investigators hope to improve patient-physician treatment decisions, so that the patient's personal treatment goals and quality of life have the highest chances of being fulfilled.
Detailed description
The aim of the study is to assess the real-world patient experience by evaluating the patients' quality of life, treatment toxicities, and clinical measures over a 6-month period. The ultimate goal of this research is to improve patient-physician treatment decisions, so that the patient's personal treatment goals and quality of life have the highest chances of being fulfilled. Aim 1. To track the toxicities/side-effects of FDA approved molecular targeted agents, immunotherapies, and combinations of treatments for NSCLC in a clinical setting for six months. Aim 2. To assess the impact of these treatment regimens on patient toxicities, symptoms, function, and quality of life, after adjustment for clinical factors and patient characteristics during the 6 month follow-up period.
Interventions
OTHERNo Intervention
No intervention
Sponsors
PatientsLikeMe
Ohio State University Comprehensive Cancer Center
AstraZeneca
Genentech, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* \>= 18 years of age * Diagnosed with metastatic (stage 3b/4) non-small cell lung cancer (NSCLC) * The total combined sample size must include at least 100 people who received one or more treatments of PD-1/PDL-1 inhibitor treatment (immunotherapy), and 50 patients who received an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI). Patients receiving any other treatments will be tracked for treatment outcomes, as well as to serve as comparison participants during data analyses of outcomes associated with PD-1/PDL-1 or EGFR-TKI). * Consented separately to the Total Cancer Care (TCC) protocol * Have access to the internet * Willing to enroll in the free online health tracking and patient community PatientsLikeMe
Exclusion criteria
* Patients enrolled in Phase I clinical trial protocols * Patients enrolled in Phase II, III or IV clinical trials involving blinded therapies (patients in open label trials will be eligible)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with Cancer Treatment Changes | 6 months post enrollment | Clinical, molecular, and patient-reported data will be collected from participants. Participants will be asked if their treatment course has changed and, if so, what changes have occurred. These questions are primarily meant to identify the number of patients who were switched from one treatment regimen (e.g., chemotherapy) to either PD-1/PDL-1 inhibitor treatment (immunotherapy) or tyrosine kinase inhibitors (TKIs). |
Countries
United States
Outcome results
None listed